Deep search
Search
Images
Copilot
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
How easy is it to get weight loss drugs?
It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are now taking either Mounjaro or Wegovy, with experts predicting a nationwide fall in obesity rates.
How weight-loss drugs will impact restaurants
The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic
Morning Update: The big promise of blockbuster weight-loss drugs
Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
12h
Scientist issues weight loss jab warning and says 'should be taken for life'
Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a ...
2d
'I feel blessed to get weight-loss jab' - but can the NHS afford it for all?
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
Medicine Buffalo
2d
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
The Next Web
5d
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
valuepenguin
2d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
Weight
loss
drugs like Ozempic and
Wegovy
cost an average of $1,083 per month if you pay full price or $325 per month after insurance. Find Cheap Health Insurance Quotes in Your Area
Weight
...
2d
What you need to know before considering weight loss jabs
Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...
1d
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
7d
Polls On Weight Loss And Will Power
Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback